Accelerated idioventricular rhythm (AIVR) is a heart rhythm that originates from the lower chambers of the heart (the ventricles) instead of the heart’s normal pacemaker. It produces a heart rate between 50 and 110 beats per minute, which places it faster than a typical ventricular escape rhythm but slower than ventricular tachycardia. Most of the time, AIVR is benign, self-limiting, and doesn’t require treatment.
How AIVR Differs From Normal Heart Rhythm
Your heart’s electrical signals normally start in a small cluster of cells near the top of the heart called the sinus node. From there, signals travel downward through the upper chambers and into the lower chambers in an orderly sequence. In AIVR, a group of cells in the ventricles starts firing on its own at an abnormally fast rate, temporarily taking over as the heart’s pacemaker. This is called “enhanced automaticity,” meaning the ventricular cells become more excitable than usual and generate impulses faster than the sinus node can keep up with.
Because the electrical signal starts in the wrong place, it takes a wider, slower path through the heart muscle. That’s why AIVR produces a distinctive wide QRS complex on an ECG, lasting longer than 120 milliseconds (compared to the narrow, quick blip of a normal heartbeat). Other hallmarks include a regular rhythm of three or more consecutive ventricular beats, and occasional “fusion beats” or “capture beats.” These occur when the sinus node and the ventricular focus fire at nearly the same time, producing hybrid beats that blend features of both.
What Causes It
The most common setting for AIVR in adults is during a heart attack, specifically when blood flow is being restored to the heart muscle. This can happen after clot-dissolving medication or after a procedure to open a blocked coronary artery. When oxygen-starved heart tissue suddenly gets blood flow again, the chemical shifts in and around the cells can make ventricular tissue more electrically active, triggering AIVR. Around 42% of patients undergoing emergency procedures for heart attacks develop AIVR during the process.
Heart attacks aren’t the only trigger. AIVR has been linked to toxicity from several drugs, including cocaine, digitalis (a medication historically used for heart failure), and certain anesthetics like halothane and desflurane. Electrolyte imbalances, particularly abnormal levels of potassium or calcium, can also set it off. Other causes include inflammation of the heart muscle (myocarditis), high fevers, and metabolic disturbances.
AIVR as a Reperfusion Sign
For decades, clinicians have watched for AIVR as a possible signal that a blocked artery has reopened during heart attack treatment. The logic is intuitive: if AIVR is triggered by the return of blood flow, seeing it on a monitor might confirm the treatment is working. The reality is more nuanced.
Research from the Indian Heart Journal found that AIVR appeared in 45% of patients with successful clot-dissolving treatment but also in 35% of patients whose treatment failed. Overall, AIVR had low sensitivity (45%) and moderate specificity (64%) as a standalone predictor of successful treatment. However, when AIVR appeared early, within two hours of receiving the clot-dissolving drug, it was far more telling. Early AIVR had a positive predictive value of 94%, meaning that when it showed up quickly, the artery had almost certainly reopened. So while AIVR alone isn’t definitive proof of successful treatment, early onset adds useful information alongside other signs like changes in the ST segment on an ECG.
How It Differs From Ventricular Tachycardia
AIVR and ventricular tachycardia (VT) can look similar on an ECG because both produce wide QRS complexes originating from the ventricles. The critical difference is speed. Ventricular tachycardia is defined by a rate above 100 to 120 beats per minute (depending on the source), while AIVR stays between 50 and 110. AIVR has sometimes been called “slow ventricular tachycardia” for this reason, though the term can be misleading because the two rhythms carry very different levels of risk.
Ventricular tachycardia can deteriorate into life-threatening rhythms and often needs urgent treatment. AIVR, by contrast, typically resolves on its own as the sinus node speeds up and reclaims control of the heart’s rhythm. The presence of fusion and capture beats on an ECG also helps confirm AIVR, since they indicate the sinus node is still competing with the ventricular focus rather than being completely overridden.
Treatment Is Rarely Needed
In most cases, AIVR produces no symptoms and doesn’t compromise blood flow. Because the rate stays in a reasonable range (50 to 110 beats per minute), the heart can still pump effectively. The rhythm usually lasts seconds to minutes and stops on its own when the sinus node resumes its normal pace.
Treatment becomes relevant only in rare situations where the loss of coordinated timing between the upper and lower chambers drops blood pressure or causes symptoms like dizziness or lightheadedness. In those cases, the goal is to speed up the sinus node so it outpaces the ventricular focus and takes back control. This can be done with medications that increase the sinus rate or, in a hospital setting, with temporary pacing of the upper chambers. Importantly, drugs that suppress ventricular activity are generally avoided because eliminating the ventricular rhythm without a faster backup could leave the heart without an adequate pacemaker.
AIVR in Children
While adults most commonly develop AIVR during heart attacks, children encounter it for different reasons. In the pediatric population, AIVR is most often associated with congenital heart defects, cardiomyopathies, and cardiac tumors. It can also be triggered by fevers, electrolyte imbalances, myocarditis, and certain medications.
In otherwise healthy children, AIVR is generally considered benign. Neonates with AIVR and no underlying heart disease are typically stable, symptom-free, and see the rhythm resolve on its own. In a review of 38 healthy children older than one year who developed AIVR, none showed signs of poor blood flow during the arrhythmia. Eight saw their ECGs return to normal spontaneously over an average follow-up of about five and a half years. However, the same review noted that 6 of those 38 children eventually developed either a dangerous arrhythmia or signs of heart muscle weakening, which underscores the importance of ongoing monitoring even when the initial presentation looks reassuring.